Comparison of patients with or without T315I revealed no significant differences in terms of likelihood for ponatinib-induced response upgrade (p = 0.7), pre-ponatinib remission status (p = 0.5), treatment-emergent AOEs (p = 0.9) or pancreatitis (p = 0.11); similarly, the presence of non-T315I ABL1 mutations did not affect either ponatinib response, incidence of AOEs (3 of 4 incidents occurred in patients without T315I mutation), or post-ponatinib survival (data not shown because of small numbers). Here, ABL1 is linked to pancreatitis.